Collateral for a security interest recorded Dec 23, 2025 (JPMorgan Chase Bank, N.A.).
Term ends Apr 15, 2029 · Medium confidence
20-year base term ends Apr 15, 2029
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 8,367,701), so the cap could be lower.
Held by Bausch + Lomb Ireland Limited
Filed Sep 19, 2014 as application 14/491,333 · Granted Sep 20, 2016
Base term, 20 years from filing
Today
2009
2029
Clock starts
Apr 15, 2009
Apr 15, 2009
Term ends
Apr 15, 2029
Apr 15, 2029
Granted
Sep 20, 2016
Sep 20, 2016
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,367,701, to Apr 15, 2029. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
8
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 15, 2009, when application 12/386,361, the earliest non-provisional in its chain, was filed (this one was filed Sep 19, 2014) | Apr 15, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,367,701) | resolves to Apr 15, 2029, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Apr 15, 2029 | Medium confidence |
This family
| US 8,080,562 | In force Jul 2030 | Jul 2030 |
| US 8,367,701 | In force no later than Apr 2029 | no later than Apr 2029 |
| US 8,871,935 | In force Apr 2029 | Apr 2029 |
| US 9,447,077 | this patent Apr 2029 | Apr 2029 |
| US 11,028,077 | In force Apr 2029 | Apr 2029 |
| Application 17/323,693 | Abandoned not computed | not computed |
| Application 18/337,565 | Abandoned not computed | not computed |
| Application 18/439,671 | Pending not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 29, 2016 Reel 39039, frame 649 | Burnier, John; Gadek, Thomas; Naud, Frederic | Sarcode Corporation | Assignment of Assignor's Interest |
| Jun 29, 2016 Reel 39206, frame 314 | Sarcode Corporation | Sarcode Bioscience Inc. | Change of Name |
| Oct 31, 2019 Reel 50900, frame 268 | Sarcode Bioscience Inc. | Novartis AG | Assignment of Assignor's Interest |
| Oct 22, 2020 Reel 54134, frame 708 | Novartis AG | Novartis Pharmaceuticals Corporation | Assignment of Assignor's Interest |
| Dec 6, 2023 Reel 65789, frame 853 | Novartis Pharmaceuticals Corporation | Bausch + Lomb Ireland Limited | Assignment of Assignor's Interest |
| Dec 23, 2025 Reel 74050, frame 573 | Bausch + Lomb Ireland Limited | JPMorgan Chase Bank, N.A., as Collateral Agent | Intellectual Property Security Agreement |
| Dec 23, 2025 Reel 74050, frame 709 | Bausch + Lomb Ireland Limited | Citibank, N.A., as Notes Collateral Agent | Intellectual Property Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Apr 2029
Term ends Apr 15, 2029. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,367,701, ends no earlier than this term, so it caps nothing.
Citations
24
later US patents cite this one
That is top 25% of utility patents granted in 2016 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.